AI brings significant advantages to clinical research, from drug discovery to patient recruitment and real-time data monitoring. This week, we spoke with Ed Fowler, Vice President, Operational Excellence, who shared his passion for how #AI is transforming the pharmaceutical industry. Ed's use of AI has allowed him to focus on more high-value activities on a day-to-day basis. Click through to read Ed's insights on the impact of AI in clinical research in the latest edition of our #AIandMe series. Share your experiences with AI in your work in the comments below! #ArtificialIntelligence #MachineLearning #DrugSafety
Parexel’s Post
More Relevant Posts
-
How is AI being utilised in the Pharma and Biotech sectors? The use of AI in the pharmaceutical sector is set to grow in the future, offering new and exciting opportunities. AI technology is becoming increasingly sophisticated and advanced, and its potential to transform the healthcare industry is immense. 🤯 AI is revolutionising the way the pharmaceutical industry operates, creating a more efficient and effective healthcare system. #AI #innovationinPharma #tech https://lnkd.in/eRrNBSbD
-
-
How is AI being utilised in the Pharma and Biotech sectors? The use of AI in the pharmaceutical sector is set to grow in the future, offering new and exciting opportunities. AI technology is becoming increasingly sophisticated and advanced, and its potential to transform the healthcare industry is immense. 🤯 AI is revolutionising the way the pharmaceutical industry operates, creating a more efficient and effective healthcare system. #AI #innovationinPharma #tech https://lnkd.in/eRrNBSbD
-
-
Here is an opportunity for those working in pharma forecasting to learn about the impact of #AI adoption. 👇 Sign up for the #webinar and join J+D Forecasting and Evaluate Ltd for this interesting discussion!
AI’s potential in pharma forecasting – Join our webinar. AI and machine learning are already making their presence felt in the pharmaceutical industry. Some areas where these technologies are making an impact include drug discovery, manufacturing and diagnostic assistance. But this is only the tip of the iceberg. In our upcoming webinar, we’ll look at how AI is redefining what’s possible in forecasting, from modelling the evolution of diseases to estimating the peak share of new drugs and much more. This is going to be an eye-opening conversation – hope to see you there! https://zurl.co/DUpw #pharma #AI
-
-
Don’t miss this insightful discussion on the impact of AI in pharma forecasting. Sign up for the webinar and join the discussion!
AI’s potential in pharma forecasting – Join our webinar. AI and machine learning are already making their presence felt in the pharmaceutical industry. Some areas where these technologies are making an impact include drug discovery, manufacturing and diagnostic assistance. But this is only the tip of the iceberg. In our upcoming webinar, we’ll look at how AI is redefining what’s possible in forecasting, from modelling the evolution of diseases to estimating the peak share of new drugs and much more. This is going to be an eye-opening conversation – hope to see you there! https://zurl.co/DUpw #pharma #AI
-
-
Our Chief Medical Officer Sheuli Porkess was privileged to contribute to this fantastic discussion, facilitated by John Rountree of Novasecta last month. Along with senior executives in the biotech and pharmaceutical sectors, the discussion explored the potential for AI to support Research and Development of new pharmaceutical interventions. A key area where the potential of AI has yet to be fully realised is the opportunity to help increase diversity of participation in clinical trials through identification of patient populations and cohorts that have high risk of disease progression, reflecting key co-morbidities. This is becoming possible, as it is across all the functions of pharmaceutical R&D, informed by real world patient, and health economic, data. A key takeaway from the discussion was that harnessing of AI's full potential requires an increasingly conscious cross-functional, multi-diciplinary approach to make this a reality - which Precisia Clinical Risk Analytics stands ready to support.
In March 2024, John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of AI for their R&D efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and cross-functional mindset, AI has great potential in pharmaceutical R&D. The best is yet to come. Read more here: https://lnkd.in/e4su9hzh
-
AI’s potential in pharma forecasting – Join our webinar. AI and machine learning are already making their presence felt in the pharmaceutical industry. Some areas where these technologies are making an impact include drug discovery, manufacturing and diagnostic assistance. But this is only the tip of the iceberg. In our upcoming webinar, we’ll look at how AI is redefining what’s possible in forecasting, from modelling the evolution of diseases to estimating the peak share of new drugs and much more. This is going to be an eye-opening conversation – hope to see you there! https://zurl.co/DUpw #pharma #AI
-
-
Looking forward to hearing how AI is changing forecasting for pharma in this webinar. Sign up and join the discussion. https://zurl.co/DUpw #Forecasting #Pharma #AI
AI’s potential in pharma forecasting – Join our webinar. AI and machine learning are already making their presence felt in the pharmaceutical industry. Some areas where these technologies are making an impact include drug discovery, manufacturing and diagnostic assistance. But this is only the tip of the iceberg. In our upcoming webinar, we’ll look at how AI is redefining what’s possible in forecasting, from modelling the evolution of diseases to estimating the peak share of new drugs and much more. This is going to be an eye-opening conversation – hope to see you there! https://zurl.co/DUpw #pharma #AI
-
-
Big data is revolutionizing AI-driven drug discovery by integrating vast amounts of diverse data from sources like genomic databases and clinical trials, enhancing predictive models, speeding up drug target identification, optimizing clinical trials, and enabling personalized medicine. This integration leads to faster, more accurate, and cost-effective drug development, ultimately improving patient outcomes and fostering innovation in the pharmaceutical industry. Learn more: https://bit.ly/3VI0bSD #Ayurion #AI #DrugDiscovery
-
-
Transform Drug Identification with mlangles Predictive AI! At mlangles, our advanced AI revolutionizes pharmaceutical drug identification, boosting accuracy and efficiency. Our deep learning model, fine-tuned with ResNet, identifies 10 drug types from images, reducing errors and saving time. Why Choose Us: - Accurate Identification: Enhance patient safety with precise drug recognition. - Efficiency Boost: Streamline workflows and reduce costs. Read full use case: https://lnkd.in/ghRNdXmw Book a free demo: https://lnkd.in/gSFSiY8B #PredictiveAI #Pharmaceuticals #AI #HealthcareInnovation
-
-
There’s a lot of noise being made about #AI right now but how can it be harnessed for the good of the #biopharmaceutical industry? In a recent op-ed published in Applied Clinical Trials Magazine our Chief Architect/SVP of Product Innovation, Tobias Guennel, PhD, discusses the merits of generative AI and how it will continue to make its way into #clinicaltrial operations: https://hubs.ly/Q02gSjks0
Generative AI Holds the Key to Transforming Trial Design
Al人工智慧 富智车用互联网公司
1mo非常有幫助！